Prevalence of hepatitis B virus and risk factors in Brazilian non-injecting drug users

Journal of Medical Virology

Volumn 81, Issue 4, 2009, Pages 602-609

  Ferreira, Renata C ^a   Rodrigues, Fabiana P ^a   Teles, Sheila A ^a   Lopes, Carmen L R ^a   Motta Castro, Ana Rita C ^b   Novais, Antônia C M ^c   Souto, Francisco J D ^c   Martins, Regina M B ^a,d  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^d Instituto de Pesquisas Tecnologicas   (Brazil)

Author keywords

Genotypes; HBV; Non injecting drug users; Occult hepatitis B; Prevalence; Risk factors

Indexed keywords

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; BRAZIL; CONDOM; DRUG USE; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SAFE SEX; SEROLOGY; SEXUALITY; BLOOD; CLASSIFICATION; CROSS-SECTIONAL STUDY; GENETICS; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; LONCHOCARPUS GLAUCIFOLIUS;

VIRUS DNA;

ADULT; BRAZIL; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG USERS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 62849109198     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21464     Document Type: Article

References (41)

1. Amesty S, Ompad DC, Galea S, Fuller CM, Wu Y, Koblin B, Vlahov D. 2008. Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City. J Community Health 33:139-148.
2. Araujo NM, Mello FC, Yoshida CF, Niel C, Gomes SA. 2004. High proportion of subgroup A' (genotype A) among Brazilian isolates of Hepatitis B virus. Arch Virol 149:1383-1395.
3. Baozhang T, Kaining Z, Jinxing K, Ruchang X, Ming L, Caixia Z, Li T. 1997. Infection with human immunodeficiency virus and hepatitis viruses in Chinese drug addicts. Epidemiol Infect 119:343-347.
4. Bastos FI, Lowndes CM, Castello-Branco LR, Linhares-de-Carvalho MI, Oelemann W, Bernier F, Morgado MG, Yoshida CF, Rozental T, Alary M. 2000. Sexual behaviour and infection rates for HIV, blood-borne and sexually transmitted infections among patients attending drug treatment centres in Rio de Janeiro, Brazil. Int J STD AIDS 11:383-392.
5. Bottecchia M, Souto FJ, O KM, Amendola M, Brandao CE, Niel C, Gomes SA. 2008. Hepatitis B virus genotypes and resistance mutations in patients under long-term lamivudine therapy: Characterization of genotype G in Brazil. BMC Microbiol 8:11.
6. Carvalho MB, Hamerschlak N, Vaz RS, Ferreira OC, Jr. 1996. Risk factor analysis and serological diagnosis of HIV-1/HIV-2 infection in a Brazilian blood donor population: Validation of the World Health Organization strategy for HIV testing. AIDS 10:1135-1140.
7. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. 2000. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 16:1043-1049.
8. Fattovich G, Bortolotti F, Donato F. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 48:335-352.
9. Fuller CM, Vlahov D, Latkin CA, Ompad DC, Celentano DD, Strathdee SA. 2003. Social circumstances of initiation of injection drug use and early shooting gallery attendance: Implications for HIV intervention among adolescent and young adult injection drug users. J Acquir Immune Defic Syndr 32:86-93.
10. Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des Jarlais DC. 2002. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among non-injecting heroin users. J Acquir Immune Defic Syndr 30:448-456.
11. Hollinger FB. 2007. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 14:S11-S15.
12. Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D, Vlahov D. 2005. Association of sex, hygiene, and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend 79:389-395.
13. Koblin BA, Xu G, Lucy D, Robertson V, Bonner S, Hoover DR, Fortin P, Latka M. 2007. Hepatitis B infection and vaccination among high-risk non-injection drug-using women: Baseline data from the UNITY study. Sex Transm Dis 34:917-922.
14. Kuo I, Sherman SG, Thomas DL, Strathdee SA. 2004. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: Missed opportunities to prevent infection. Drug Alcohol Depend 73:69-78.
15. Lavanchy D. 2005. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34:S1-S3.
16. Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, Parry JV. 2001. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: A national cross-sectional survey. BMJ 323:1209-1213.
17. Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. 2008. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 15:229-236.
18. Martelli CM, TurchiM, Souto FJ, Saez-Alquezar A, Andrade AL, Zicker F. 1999. Anti-HBc testing for blood donations in areas with intermediate hepatitis B endemicity. Rev Panam Salud Publica 6:69-73.
19. Mello FC, Souto FJ, Nabuco LC, Villela-Nogueira CA, Coelho HS, Franz HC, Saraiva JC, Virgolino HA, Motta-Castro AR, Melo MM, Martins RMB, Gomes SA. 2007. Hepatitis B virus genotypes circulating in Brazil: Molecular characterization of genotype F isolates. BMC Microbiol 7:103.
20. Motta-Castro AR, Martins RM, Yoshida CF, Teles SA, Paniago AM, Lima KM, Gomes SA. 2005. Hepatitis B virus infection in isolated Afro-Brazilian communities. J Med Virol 77:188-193.
21. Neaigus A, Miller M, Friedman SR, Hagen DL, Sifaneck SJ, Ildefonso G, des Jarlais DC. 2001. Potential risk factors for the transition to injecting among non-injecting heroin users: A comparison of former injectors and never injectors. Addiction 96:847-860.
22. Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC. 2007. Sexual and other non-injection risks for HBV and HCV seroconversions among non-injecting heroin users. J Infect Dis 195:1052-1061.
23. Niel C, Moraes MT, Gaspar AM, Yoshida CF, Gomes SA. 1994. Genetic diversity of hepatitis B virus strains isolated in Rio de Janeiro, Brazil. J Med Virol 44:180-186.
24. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47:289-309.
25. Oliveira SA, Hacker MA, Oliveira ML, Yoshida CF, Telles PR, Bastos FI. 2005. A window of opportunity: Declining rates of hepatitis B virus infection among injection drug users in Rio de Janeiro, and prospects for targeted hepatitis B vaccination. Rev Panam Salud Publica 18:271-277.
26. Quaglio GL, Lugoboni F, Pajusco B, Sarti M, Talamini G, Mezzelani P, Des Jarlais DC. 2003. Hepatitis C virus infection: Prevalence, predictor variables and prevention opportunities among drug users in Italy. J Viral Hepat 10:394-400.
27. Quaglio G, Lugoboni F, Mezzelani P, Des Jarlais DC, Lechi A. 2006. Hepatitis vaccination among drug users. Vaccine 24:2702-2709.
28. Raimondo G, Pollicino T, Cacciola I, Squadrito G. 2007. Occult hepatitis B virus infection. J Hepatol 46:160-170.
29. Rich JD, Anderson BJ, Schwartzapfel B, Stein MD. 2006. Sexual risk for hepatitis B virus infection among hepatitis C virus-negative heroin and cocaine users. Epidemiol Infect 134:478-484.
30. Santana Rodriguez OE, Male Gil ML, HernandezSantana JF, Liminana Canal JM, Martin Sanchez AM. 1998. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol 14:555-561.
31. Schaefer S. 2007. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13:14-21.
32. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, Strauss S. 2007. Non-injection drug use and hepatitis C virus: A systematic review. Drug Alcohol Depend 89:1-12.
33. Sitnik R, Pinho JR, Bertolini DA, Bernardini AP, Da Silva LC, Carrilho FJ. 2004. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. J Clin Microbiol 42:2455-2460.
34. Smikle MF, Dowe G, Williams EM, Thesiger C. 2000. Antibodies to hepatitis B virus and hepatitis C virus in residential detoxification clients in Jamaica. Hum Antibodies 9:231-233.
35. Souto FJD. 1999. Distribuição da hepatite B no Brasil: Atualizaçãodo mapa epidemiológico e proposições para o seu controle. Gastroenterol Endosc Dig 18:143-150.
36. Teles SA, Martins RM, Gomes SA, Gaspar AM, Araujo NM, Souza KP, Carneiro MA, Yoshida CF. 2002. Hepatitis B virus transmission in Brazilian hemodialysis units: Serological and molecular follow-up. J Med Virol 68:41-49.
37. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. 2004. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51-57.
38. Tortu S, McMahon JM, Pouget ER, Hamid R. 2004. Sharing of non-injection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 39:211-224.
39. Trinks J, Cuestas ML, Tanaka Y, Mathet VL, Minassian ML, Rivero CW, Benetucci JA, Gímenez ED, Segura M, Bobillo MC, Corach D, Ghiringhelli PD, Sánchez DO, Avila MM, Peralta LA, Kurbanov F, Weissenbacher MC, Simmonds P, Mizokami M, Oubiña JR. 2008. Two simultaneous hepatitis B virus epidemics among injecting drug users and men who have sex with men in Buenos Aires, Argentina: Characterization of the first D/A recombinant from the American continent. J Viral Hepat 15:827-838.
40. Van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA.1994. Risk factors for the transition from non-injection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol 139:1153-1163.
41. Vitale F, Tramuto F, Orlando A, Vizzini G, Meli V, Cerame G, Mazzucco W, Virdone R, Palazzo U, Villafrate MR, Tagger A, Romano N. 2008. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection? J Med Virol 80:577-582.